Overview
Beckley Psytech is a UK-based clinical-stage company developing short-duration psychedelic therapies, with a lead program using intranasal psilocybin (BPL-003) for treatment-resistant depression intended to reduce session time versus oral formulations. They are part of the Beckley Foundation's broader mission to advance psychedelic science.
More in Psychedelics
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
🍄 Psychedelics
Location
Oxford, UK
Funding
Series B · $80M
Website
www.beckleypsytech.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →